Figma’s Stock Skyrockets 250% In Market Debut
The stock of creative software company Figma (FIG) soared 250% in its first trading day. Figma’s share price more than tripled in its New York Stock Exchange (NYSE) debut, rising from an initial public offering (IPO) price of $33 U.S. to close at $115.50 U.S., an increase of 250%. Figma is the latest technology company to hold a successful IPO, following new issuance from stablecoin issuer Circle (CRCL) and artificial intelligence (A.I.) company CoreWeave (CRWV).The big move higher in its trading debut pushed Figma’s market capitalization to $68 billion U.S. The offering raised $1.2 billion U.S. for the company.Figma makes web-based software that allows people to collaborate on slide decks, digital whiteboards, and design apps and websites.Despite the IPO win, there have been questions raised about Figma’s long-term prospects given the emergence of A.I. and its ability to accomplish similar creative tasks at a lower price point. Figma claims to have more than 13 million monthly users, two-thirds of whom are not designers. According to the company, Microsoft (MSFT), Netflix (NFLX), and Uber (UBER) are customers.In its IPO filing, Figma said it generated $9 million U.S. to $12 million U.S. in operating income on $247 million U.S. to $250 million U.S. in revenue, with sales growing 40% year over year.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


